Isg15 was found to be increased in numerous primary human cancers, including endometrial tumors [11]; pancreatic adenocarcinomas[12]; tumors of the breast with Isg15 expression independent of HER2, progesterone, and estrogen receptor status [13, 14]; cancer of the bladder [15] and prostate [16]. This evidence concerns the gene ERBB2 and breast neoplasm.